Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Summary

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits for HF(generally meaning a hospital stay or urgent presentation to a healthcare unit due to worsening symptoms of heart failure) in patients suffering from HF with an ejection fraction greater than or equal to 40%. Researchers will also collect information on how much the heart disease has impact on patient's lives, change of kidney function, and how well finerenone treatment is tolerated. The study plans to enroll 6000 male and female patients of the age of 40 years and above suffering from heart failure with ejection fraction greater than or equal to 40%. Participants will take the study product as oral tablet with a dose between 0 (Placebo) 40 mg once daily. Study duration will be up to 43 months.

Timeline

Start

2020-09-14

Primary completion

2024-05-15

Completion

2024-06-14

Publications

• Results Bhatt AS, Chatur S, Claggett BL, Lay-Flurrie J, Viswanathan P, Vardeny O, Kosiborod MN, Sharma K, Solomon SD, Vaduganathan M. Gamified Behavioral Science Intervention to Enhance Trial Enrollment: An Embedded Study Within the FINEARTS-HF Trial. JACC Heart Fail. 2024 Nov;12(11):1939-1941. doi: 10.1016/j.jchf.2024.05.002. Epub 2024 May 11. No abstract available.
• Results Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Solomon SD, McMurray JJV. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024 Sep 21;404(10458):1119-1131. doi: 10.1016/S0140-6736(24)01733-1. Epub 2024 Sep 1.
• Results Kondo T, Henderson AD, Docherty KF, Jhund PS, Vaduganathan M, Solomon SD, McMurray JJV. Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? J Am Coll Cardiol. 2024 Nov 26;84(22):2233-2240. doi: 10.1016/j.jacc.2024.08.033. Epub 2024 Sep 1.
• Results Ostrominski JW, Aggarwal R, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure. J Card Fail. 2024 Sep;30(9):1170-1174. doi: 10.1016/j.cardfail.2024.04.015. Epub 2024 May 11. No abstract available.
• Results Ostrominski JW, Claggett BL, Miao ZM, Mc Causland FR, Anand IS, Desai AS, Jhund PS, Lam CSP, Pfeffer MA, Pitt B, Zannad F, Zile MR, Bomfim Wirtz A, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis. J Am Coll Cardiol. 2024 Jul 9;84(2):223-228. doi: 10.1016/j.jacc.2024.05.005. Epub 2024 May 12. No abstract available.
• Results Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P; FINEARTS-HF Committees and Investigators. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi: 10.1056/NEJMoa2407107. Epub 2024 Sep 1.
• Results Solomon SD, Ostrominski JW, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Ma CS, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang SM, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov LG, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Viswanathan P, McMurray JJV. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial. Eur J Heart Fail. 2024 Jun;26(6):1334-1346. doi: 10.1002/ejhf.3266. Epub 2024 May 11.
• Results Vaduganathan M, Claggett BL, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Desai AS, Jhund PS, Viswanathan P, Bomfim Wirtz A, Schloemer P, Lay-Flurrie J, McMurray JJV, Solomon SD. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Eur J Heart Fail. 2024 Jun;26(6):1324-1333. doi: 10.1002/ejhf.3253. Epub 2024 May 14.
• Results Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024 Dec;30(12):3758-3764. doi: 10.1038/s41591-024-03264-4. Epub 2024 Sep 1.
• Results Vaduganathan M, Neuen BL, McCausland F, Jhund PS, Docherty KF, McMurray JJV, Solomon SD. Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure? J Am Coll Cardiol. 2024 Nov 26;84(22):2241-2245. doi: 10.1016/j.jacc.2024.08.034. Epub 2024 Sep 1. No abstract available.
• Boettger P, Sedighi J, Sohns C, Bauersachs J, Assmus B, Sossalla S. Cost-effectiveness of finerenone in heart failure with mildly reduced or preserved ejection fraction - Insights from FINEARTS-HF. Eur J Heart Fail. 2026 May 24:xuag167. doi: 10.1093/ejhf/xuag167. Online ahead of print.
• Bains M, Butt JH, Ostrominski JW, Pabon Porras MA, Humphreys-Davies L. Treatment with finerenone in people with heart failure and mildly reduced or preserved ejection fraction: a plain language review. Future Cardiol. 2026 Apr;22(4):323-351. doi: 10.1080/14796678.2026.2650667. Epub 2026 Apr 28.
• Hamatani Y, Claggett BL, Desai AS, Lewis EF, Jhund PS, Lam CSP, Martinez FA, Zannad F, Pfeffer MA, McMurray JJV, Solomon SD, Vaduganathan M. Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure. J Am Coll Cardiol. 2026 Jun 30;87(25):3559-3569. doi: 10.1016/j.jacc.2026.03.026. Epub 2026 Mar 16.
• Lu H, Kosztin A, Claggett BL, Foa A, Pabon MA, Desai AS, Jhund PS, Henderson AD, Merkely B, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Amarante F, Saarinen R, De Sanctis Y, Glasauer A, McMurray JJV, Vaduganathan M, Solomon SD. Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2026 Jun 1;11(6):574-582. doi: 10.1001/jamacardio.2026.0682.
• Chimura M, McDowell K, Jhund PS, Henderson AD, Claggett BL, Desai AS, Brinker M, Lay-Flurrie J, Glasauer A, Goea L, Berger M, Lam CSP, Senni M, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF. JAMA Cardiol. 2026 May 1;11(5):416-426. doi: 10.1001/jamacardio.2026.1049.
• Hamatani Y, Peikert A, Claggett BL, Desai AS, Jhund PS, Henderson AD, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Lay-Flurrie J, Lage A, Hofmeister L, McMurray JJV, Solomon SD, Vaduganathan M. Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. Eur J Heart Fail. 2026 Mar 12:xuag062. doi: 10.1093/ejhf/xuag062. Online ahead of print.
• Chimura M, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lay-Flurrie J, Scalise A, Rohwedder K, Lam CSP, Senni M, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial. Eur J Heart Fail. 2026 May 2;28(1):26-38. doi: 10.1093/ejhf/xuag008.
• Henderson AD, Docherty KF, Talebi A, Kondo T, Petrie MC, Claggett BL, Desai AS, Vaduganathan M, Atherton JJ, Bauersachs J, Schou M, Verma S, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Brinker M, Amarante F, Rohwedder K, Lay-Flurrie J, Solomon SD, McMurray JJV, Jhund PS. A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF. Eur Heart J Cardiovasc Pharmacother. 2026 May 19;12(3):176-185. doi: 10.1093/ehjcvp/pvag010.
• Chimura M, Henderson AD, Jhund PS, Claggett BL, Desai AS, Filippatos G, Gajos G, Brinker M, Amarante F, Lay-Flurrie J, Rohwedder K, Lam CSP, Sato N, Senni M, Voors AA, Zannad F, Yilmaz MB, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF. JACC Heart Fail. 2026 Jun;14(6):102938. doi: 10.1016/j.jchf.2026.102938. Epub 2026 Feb 4.
• Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Borentain M, Rohwedder K, Dayoub R, De Sanctis Y, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF. Circ Heart Fail. 2026 Feb;19(2):e013201. doi: 10.1161/CIRCHEARTFAILURE.125.013201. Epub 2026 Jan 29.
• Foa A, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Henderson AD, Chatur S, Amarante F, Hofmeister L, Horvat-Broecker A, Kuhls S, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2026 Apr;14(4):102779. doi: 10.1016/j.jchf.2025.102779. Epub 2025 Dec 9.
• Ostrominski JW, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Rohwedder K, Brinker M, Schloemer P, McMurray JJV, Solomon SD, Vaduganathan M. Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial. Eur J Heart Fail. 2025 Dec;27(12):2788-2799. doi: 10.1002/ejhf.70034. Epub 2025 Sep 8.
• Lu H, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Voors AA, Senni M, Zannad F, Pitt B, Shah SJ, Lam CSP, Scheerer MF, Scalise A, Mueller K, Berger M, Goea L, McMurray JJV, Solomon SD. Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2025 Oct;13(10):102590. doi: 10.1016/j.jchf.2025.102590. Epub 2025 Aug 25.
• Chimura M, Jhund PS, Henderson AD, Yang M, Claggett BL, Desai AS, Rohwedder K, Lage A, Scalise A, Mueller K, Schou M, Lam CSP, Senni M, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Aug 13;10(10):979-89. doi: 10.1001/jamacardio.2025.2551. Online ahead of print.
• Butt JH, Jhund PS, Henderson AD, Claggett BL, Chiang CE, Linssen GCM, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, von Lewinski D, Lay-Flurrie J, Scalise A, Rohwedder K, Desai AS, Lam CSP, Senni M, Shah SJ, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Aug 1;10(8):829-840. doi: 10.1001/jamacardio.2025.1775.
• Ferreira JP, Zannad F. Screening for Undiagnosed Heart Failure: A Viewpoint. J Card Fail. 2025 Aug;31(8):1339-1344. doi: 10.1016/j.cardfail.2025.04.016. Epub 2025 May 23.
• Pabon MA, Vardeny O, Vaduganathan M, Desai AS, Claggett BL, Kulac IJ, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Saldarriaga CI, Petrie MC, Merkely B, Borentain M, Mueller K, Viswanathan P, Amarante F, Morris A, McMurray JJV, Solomon SD. Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):740-745. doi: 10.1001/jamacardio.2025.1101.
• Chimura M, Yang M, Henderson AD, Jhund PS, Docherty KF, Claggett BL, Desai AS, Filippatos G, Gajos G, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Lam CSP, Sato N, Senni M, Voors AA, Zannad F, Yilmaz MB, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV; FINEARTS-HF Committees and Investigators. Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. 2025 Nov;27(11):2301-2312. doi: 10.1002/ejhf.3682. Epub 2025 May 16.
• Kondo T, Jhund PS, Henderson AD, Claggett BL, Desai AS, Brinker M, Lay-Flurrie J, Schloemer P, Viswanathan P, Amarante F, Chiang CE, Filippatos G, Lam CSP, Petrie MC, Senni M, Schou M, Verma S, Voors AA, von Lewinski D, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF. Eur J Heart Fail. 2025 Aug;27(8):1459-1471. doi: 10.1002/ejhf.3669. Epub 2025 Apr 29.
• Ostrominski JW, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Rohwedder K, Lay-Flurrie J, Lavagnino MA, McMurray JJV, Solomon SD. Finerenone and NYHA Functional Class in Heart Failure: The FINEARTS-HF Trial. JACC Heart Fail. 2026 Jan;14(1):102440. doi: 10.1016/j.jchf.2025.03.007. Epub 2025 Apr 2.
• Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, Mueller K, Scheerer MF, Viswanathan P, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. 2025 Aug;27(8):1444-1458. doi: 10.1002/ejhf.3661. Epub 2025 Apr 13.
• Ostrominski JW, Mc Causland FR, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Schloemer P, Brinker M, Scheerer MF, McMurray JJV, Solomon SD, Vaduganathan M. Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial. JACC Heart Fail. 2026 Jan;14(1):102439. doi: 10.1016/j.jchf.2025.03.006. Epub 2025 Apr 2.
• Desai AS, Jhund PS, Vaduganathan M, Claggett BL, Cunningham JW, Pabon MA, Lam CSP, Senni M, Shah S, Voors AA, Zannad F, Pitt B, Amarante F, Lay-Flurrie J, Scheerer MF, Lage A, McMurray JJV, Solomon SD. Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):678-685. doi: 10.1001/jamacardio.2025.0860.
• Matsumoto S, Henderson AD, Jhund PS, Bauersachs J, Chioncel O, Claggett BL, Comin-Colet J, Desai AS, Filippatos G, Lam CSP, Pitt B, Scheerer MF, Lay-Flurrie J, Amarante F, Brinker M, Schou M, Senni M, Shah SJ, Voors AA, Zannad F, Zieroth S, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):696-707. doi: 10.1001/jamacardio.2025.0848.
• McDowell K, Docherty KF, Campbell RT, Henderson AD, Jhund PS, Claggett BL, Desai AS, Lay-Flurrie J, Hofmeister L, Scalise A, Lam CSP, Petrie MC, Schou M, Senni M, Shah SJ, Udell JA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. JAMA Cardiol. 2025 Jun 1;10(6):535-544. doi: 10.1001/jamacardio.2025.0025.
• Cunningham JW, Chatur S, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Llamas Esperon G, Lam CSP, Sato N, Senni M, Shah S, Voors A, Zannad F, Pitt B, Zieroth S, Brinker M, Rohwedder K, Kim SY, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD. Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Feb 26;10(4):370-8. doi: 10.1001/jamacardio.2025.0016. Online ahead of print.
• Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Viswanathan P, Kolkhof P, Schloemer P, Amarante F, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV; FINEARTS-HF Committees and Investigators. Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes Endocrinol. 2025 Feb;13(2):107-118. doi: 10.1016/S2213-8587(24)00309-7. Epub 2025 Jan 13.
• Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Lay-Flurrie J, Viswanathan P, Lage A, Scheerer MF, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Kosiborod MN, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF. J Am Coll Cardiol. 2025 Jan 21;85(2):140-155. doi: 10.1016/j.jacc.2024.10.111. Epub 2024 Dec 10.
• Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jan 1;10(1):59-70. doi: 10.1001/jamacardio.2024.4613.
• Vardeny O, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Matsumoto S, Merkely B, Zieroth S, Yilmaz MB, Lay-Flurrie J, Viswanathan P, Horvat-Broecker A, Scalise A, McMurray JJV, Solomon SD. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2025 Jan 1;10(1):42-48. doi: 10.1001/jamacardio.2024.4539.
• Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Henderson AD, Brinker M, Perkins R, Scheerer MF, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial. J Am Coll Cardiol. 2025 Jan 21;85(2):159-168. doi: 10.1016/j.jacc.2024.10.091. Epub 2024 Oct 25.
• Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, Viswanathan P, Scalise A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation. 2025 Jan 7;151(1):45-58. doi: 10.1161/CIRCULATIONAHA.124.072011. Epub 2024 Sep 29.
• Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Desai AS, Jhund PS, Henderson AD, Brinker M, Lay-Flurrie J, Viswanathan P, Scheerer MF, Lage A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 2025 Jan 14;151(2):149-158. doi: 10.1161/CIRCULATIONAHA.124.072055. Epub 2024 Sep 28.
• Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Lay-Flurrie J, Viswanathan P, Behmenburg FU, McMurray JJV, Solomon SD. Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Feb 1;10(2):176-181. doi: 10.1001/jamacardio.2024.3782.

Drugs

Indications